These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 16316297)

  • 1. Pharmacogenomics in cardiovascular disease: the role of single nucleotide polymorphisms in improving drug therapy.
    Mango R; Vecchione L; Raso B; Borgiani P; Brunetti E; Mehta JL; Lauro R; Romeo F; Novelli G
    Expert Opin Pharmacother; 2005 Dec; 6(15):2565-76. PubMed ID: 16316297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular pharmacogenomics and individualized drug therapy.
    Pereira NL; Weinshilboum RM
    Nat Rev Cardiol; 2009 Oct; 6(10):632-8. PubMed ID: 19707183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From SNPs to functional studies in cardiovascular pharmacogenomics.
    Cresci S
    Methods Mol Biol; 2008; 448():379-93. PubMed ID: 18370238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetics, pharmacogenomics, and cardiovascular therapeutics: the way forward.
    Terra SG; Johnson JA
    Am J Cardiovasc Drugs; 2002; 2(5):287-96. PubMed ID: 14727958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenomics: the genetics of variable drug responses.
    Roden DM; Wilke RA; Kroemer HK; Stein CM
    Circulation; 2011 Apr; 123(15):1661-70. PubMed ID: 21502584
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular pharmacogenomics; state of current knowledge and implementation in practice.
    Shahabi P; Dubé MP
    Int J Cardiol; 2015 Apr; 184():772-795. PubMed ID: 25838112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenomics and cardiovascular drugs: need for integrated biological system with phenotypes and proteomic markers.
    Siest G; Marteau JB; Maumus S; Berrahmoune H; Jeannesson E; Samara A; Batt AM; Visvikis-Siest S
    Eur J Pharmacol; 2005 Dec; 527(1-3):1-22. PubMed ID: 16316654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacogenomics to Revive Drug Development in Cardiovascular Disease.
    Dubé MP; de Denus S; Tardif JC
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):59-64. PubMed ID: 26768480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice.
    Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S
    Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenomics and cardiology: improving treatment with existing drugs.
    Sorrentino MJ; O'Donnell PH
    Pharmacogenomics; 2015; 16(11):1223-6. PubMed ID: 26369612
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacogenomics and personalized use of drugs.
    Wang JF; Wei DQ; Chou KC
    Curr Top Med Chem; 2008; 8(18):1573-9. PubMed ID: 19075768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?
    Roden DM
    Can J Cardiol; 2013 Jan; 29(1):58-66. PubMed ID: 23200096
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics and management of cardiovascular disease.
    Howe LA
    Nurse Pract; 2009 Aug; 34(8):28-35; quiz 36. PubMed ID: 19638892
    [No Abstract]   [Full Text] [Related]  

  • 14. Cardiovascular pharmacogenetics.
    Myburgh R; Hochfeld WE; Dodgen TM; Ker J; Pepper MS
    Pharmacol Ther; 2012 Mar; 133(3):280-90. PubMed ID: 22123178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.
    Berinstein E; Levy A
    Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):973-983. PubMed ID: 28792790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics and cardiovascular disease management.
    Weston CF
    Hosp Med; 2004 Oct; 65(10):594-8. PubMed ID: 15524338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetics and cardiovascular disease: impact on drug response and applications to disease management.
    Humma LM; Terra SG
    Am J Health Syst Pharm; 2002 Jul; 59(13):1241-52. PubMed ID: 12116890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Pharmacogenomics: Does It Matter If You're Black or White?
    De T; Park CS; Perera MA
    Annu Rev Pharmacol Toxicol; 2019 Jan; 59():577-603. PubMed ID: 30296897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacogenomics and pharmacoproteomics: a strategy for cardio-vascular drugs].
    Siest G; Marteau JB; Maumus S; Berrahmoune H; Jeannesson E; Samara A; Batt AM; Visvikis-Siest S
    Ann Pharm Fr; 2007 May; 65(3):203-10. PubMed ID: 17489077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Implementation of Cardiovascular Pharmacogenomics.
    Pereira NL; Stewart AK
    Mayo Clin Proc; 2015 Jun; 90(6):701-4. PubMed ID: 26046404
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.